University of Oregon Patent applications |
Patent application number | Title | Published |
20160137598 | SYNTHESIS OF CYCLOPHANES FROM A SELF-ASSEMBLY REACTION - Disclosed herein is a novel method for preparing cyclophanes, comprising forming a disulfide cyclophane by contacting a linker moiety which includes two or more thiol groups, with a metal salt and an oxidant. The disulfide cyclophane is then desulfurized to form a thiacyclophane comprising thioether bridges. This thiacyclophane optionally may be further desulfurized to form an unsaturated hydrocarbon cyclophane, which can then be reduced to form a saturated hydrocarbon cyclophane. The various cyclophanes can be synthesized in a ring form, such as a dimer, trimer or tetramer etc., or they can be synthesized in a tetrahedral or larger structure. Also disclosed are novel cyclophanes formed by the disclosed method. | 05-19-2016 |
20160041099 | LIGHT SHEET FLUORESCENCE AND DIFFERENTIAL INTERFERENCE CONTRAST MICROSCOPE - One or more excitation optical beams are scanned or otherwise directed to a specimen volume to establish a light sheet. Fluorescence from a specimen portion in the light sheet is collected and used to form an image. An interference contrast image of the same or an adjacent specimen portion is obtained by directing an interference contrast optical beam to the specimen so as to be substantially perpendicular to the light sheet. A common imaging device can be used to capture both images, and the resulting image permits correlation of fluorescence image features with specimen structure. | 02-11-2016 |
20150355153 | PHENYLACETYLENES - A compound, or a protonate or salt thereof, having the formula of: | 12-10-2015 |
20150353580 | GOLD NANOPARTICLES AND METHODS OF MAKING AND USING GOLD NANOPARTICLES - Disclosed herein are embodiments of gold nanoparticles and methods of making and using the gold nanoparticles. The disclosed gold nanoparticles have core sizes and polydispersities controlled by the methods of making the gold nanoparticles. In some embodiments, the methods of making the gold nanoparticles can concern using flow reactors and reaction conditions controlled to make gold nanoparticles having a desired core size. The gold nanoparticles disclosed herein also comprise various ligands that can be used to facilitate the use of the gold nanoparticles in a variety of applications. | 12-10-2015 |
20150303347 | GaAs THIN FILMS AND METHODS OF MAKING AND USING THE SAME - Disclosed herein are embodiments of methods for making GaAs thin films, such as photovoltaic GaAs thin films. The methods disclosed herein utilize sources, precursors, and reagents that do not produce (or require) toxic gas and that are readily available and relatively low in cost. In some embodiments, the methods are readily scalable for industrial applications and can provide GaAs thin films having properties that are at least comparable to or potentially superior to GaAs films obtained from conventional methods. | 10-22-2015 |
20150259217 | LOW-TEMPERATURE ROUTE FOR PRECISION SYNTHESIS OF METAL OXIDE NANOPARTICLES - Methods for making metal oxide nanoparticles, including mixed metal oxides and core-shell metal oxide nanoparticles, are disclosed. A solution comprising a metal carboxylate and a carboxylic acid is combined with a solvent comprising an alcohol heated to a temperature ≦250° C. for an effective period of time to form metal oxide nanoparticles. The metal may be a group IIIA metal, a group IVA metal, a transition metal, or a combination thereof. A metal oxide shell may be deposited onto metal oxide nanoparticles by dispersing the metal oxide nanoparticles in an alcohol, adding a metal carboxylate, and maintaining the reaction at a temperature ≦200° C. for an effective period of time to form core-shell nanoparticles. The nanoparticles may have a relative size dispersity of ≦20%, and may further comprise a plurality of carboxylic acid, carboxylate, and/or alcohol ligands coordinated to the nanoparticles' outer surfaces. | 09-17-2015 |
20130281462 | ARYL DIAMIDINES AND PRODRUGS THEREOF FOR TREATING MYOTONIC DYSTROPHY - Disclosed herein are compounds (for example, diamidine derivatives and prodrugs) and methods of use thereof, for example in treating muscular dystrophy (DM) or disease caused by a toxic RNA in a subject. In some embodiments, the methods include administering an effective amount of one of more of the disclosed compounds to a subject to treat or inhibit DM or a disease caused by or associated with toxic RNA, such as DM1, DM2, spinocerebellar ataxia type 8 (SCA8), fragile X tremor ataxia syndrome (FXTAS), or Huntington disease-like 2 (HLD2). In some examples, the methods include selecting a subject for treatment, for example selecting a subject with DM1, DM2, SCA8, FXTAS, or HLD2. | 10-24-2013 |
20130150592 | HETEROATOMIC INDENOFLUORENES - A compound having a structure of: | 06-13-2013 |
20130118411 | ELECTROPHARYNGEOGRAM ARRAYS AND METHODS OF USE - Disclosed herein are devices, systems, and methods for measuring an electropharyngeogram (EPG) in living organisms. In some embodiments, the devices and systems disclosed herein include an array for sorting and immobilizing an organism (such as a nematode) for measurement of an EPG and/or optical imaging. Also disclosed are methods for identifying therapeutic or toxic compounds utilizing the disclosed devices and systems. In some embodiments, the methods include screening for compounds with anthelmintic activity, toxicity (for example HERG channel blockers), or candidate drugs for treatment of a variety of human and/or animal diseases. | 05-16-2013 |
20120107230 | Treatment of Hyperproliferative Diseases with Vinca Alkaloid N-Oxide Analogs - The present invention relates to vinca alkaloid and analog N-oxides having activity for treating hyperproliferative disorders. Further, the invention relates to pharmaceutical compositions and methods of using vinca alkaloid and analog N-oxides, alone or in combination with one or more other active agents or treatments, to treat hyperproliferative disorders. | 05-03-2012 |
20110035815 | Mosaic knockout mouse tumor models and methods or use - Disclosed herein are transgenic mouse tumor models. A portion of the cells of the disclosed transgenic mice undergo directed somatic recombination and the mouse is therefore a mosaic for homozygous knockout of p53, NF1, or both p53 and NF1 genes. The homozygous null cells resulting from the somatic recombination also express a detectable fluorescent protein, and the resulting sibling cells, which are wild type for p53, NF1, or both p53 and NF1, express a different detectable fluorescent protein. Also disclosed herein are methods of identifying compounds for treating or preventing a tumor, using the disclosed transgenic mice. | 02-10-2011 |
20100145024 | LONG WAVELENGTH ENGINEERED FLUORESCENT PROTEINS - Engineered fluorescent proteins, nucleic acids encoding them and methods of use. | 06-10-2010 |
20090155573 | SCAFFOLD-ORGANIZED METAL, ALLOY, SEMICONDUCTOR AND/OR MAGNETIC CLUSTERS AND ELECTRONIC DEVICES MADE USING SUCH CLUSTERS - A method for forming arrays of metal, alloy, semiconductor or magnetic clusters is described. The method comprises placing a scaffold on a substrate, the scaffold comprising molecules selected from the group consisting of polynucleotides, polypeptides, and perhaps combinations thereof. Polypeptides capable of forming α helices are currently preferred for forming scaffolds. Arrays are then formed by contacting the scaffold with plural, monodispersed ligand-stabilized clusters. Each cluster, prior to contacting the scaffold, includes plural exchangeable ligands bonded thereto. If the clusters are metal clusters, then the metal preferably is selected from the group consisting of Ag, Au, Pt, Pd and mixtures thereof. A currently preferred metal is gold, and a currently preferred metal cluster is Au | 06-18-2009 |
20090047753 | Scaffold-organized clusters and electronic devices made using such clusters - A method for forming arrays of metal, alloy, semiconductor or magnetic clusters is described. The method comprises placing a scaffold on a substrate, the scaffold comprising, for example, polynucleotides and/or polypeptides, and coupling the clusters to the scaffold. Methods of producing arrays in predetermined patterns and electronic devices that incorporate such patterned arrays are also described. | 02-19-2009 |
20080300202 | SUBTRACTIVE TRANSGENICS - Described herein are methods for predictable, highly selective expression of a transgene in a human or non-human animal. The methods comprise subtractive transgenics, wherein the expression pattern of one selective promoter is subtracted from the expression pattern of a second selective promoter. Provided are non-human transgenic animals exhibiting a highly selective expression pattern and methods of producing such animals. Further provided are methods of selective expression of a transgene in an animal, including a human, by administration of viral vectors. | 12-04-2008 |